CytomX Therapeutics (CTMX) Receivables - Other (2015 - 2026)

CytomX Therapeutics has reported Receivables - Other for 12 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 66.67% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 66.67% YoY), and the FY2025 full-year result was $800000.0, down 27.27% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.5 million, up from $800000.0 in the prior quarter.
• The five-year high for Receivables - Other was $35.0 million in Q4 2022, with the low at $800000.0 in Q4 2025.
• Historically, Receivables - Other has averaged $3.1 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 4275.0% — and 2023, when it tumbled 96.86%.
• CytomX Therapeutics' Receivables - Other stood at $35.0 million in 2022, then plunged by 96.86% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then decreased by 27.27% to $800000.0 in 2025, then surged by 87.5% to $1.5 million in 2026.
• The last three Receivables - Other figures came in at $1.5 million (Q1 2026), $800000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.